These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 24211402)
1. Serum HE4 as a prognostic marker in endometrial cancer--a population based study. Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402 [TBL] [Abstract][Full Text] [Related]
2. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Antonsen SL; Høgdall E; Christensen IJ; Lydolph M; Tabor A; Loft Jakobsen A; Fagö-Olsen CL; Andersen ES; Jochumsen K; Høgdall C Acta Obstet Gynecol Scand; 2013 Nov; 92(11):1313-22. PubMed ID: 24032654 [TBL] [Abstract][Full Text] [Related]
3. HE4 is an independent prognostic marker in endometrial cancer patients. Mutz-Dehbalaie I; Egle D; Fessler S; Hubalek M; Fiegl H; Marth C; Widschwendter A Gynecol Oncol; 2012 Aug; 126(2):186-91. PubMed ID: 22525819 [TBL] [Abstract][Full Text] [Related]
4. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. Brennan DJ; Hackethal A; Mann KP; Mutz-Dehbalaie I; Fiegl H; Marth C; Obermair A BMC Cancer; 2015 Feb; 15():33. PubMed ID: 25655024 [TBL] [Abstract][Full Text] [Related]
5. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management. Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483 [TBL] [Abstract][Full Text] [Related]
6. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients. Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191 [TBL] [Abstract][Full Text] [Related]
7. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy. Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kinalski M; Terlikowski SJ Adv Med Sci; 2016 Mar; 61(1):23-7. PubMed ID: 26344910 [TBL] [Abstract][Full Text] [Related]
8. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma. Saarelainen SK; Peltonen N; Lehtimäki T; Perheentupa A; Vuento MH; Mäenpää JU Am J Obstet Gynecol; 2013 Aug; 209(2):142.e1-6. PubMed ID: 23583212 [TBL] [Abstract][Full Text] [Related]
9. [Clinical value of combined detection of serum human epididymal secretory protein E4 and CA(125) in the diagnosis of endometrial carcinoma]. Zhang AM; Zhang P Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):125-8. PubMed ID: 22455745 [TBL] [Abstract][Full Text] [Related]
10. Value of pre-operative serum CA125 level for prediction of prognosis in patients with endometrial cancer. Chen YL; Huang CY; Chien TY; Huang SH; Wu CJ; Ho CM Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):397-402. PubMed ID: 21806586 [TBL] [Abstract][Full Text] [Related]
11. Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer. Stiekema A; Lok C; Korse CM; van Driel WJ; van der Noort V; Kenter GG; Van de Vijver KK Virchows Arch; 2017 Jun; 470(6):655-664. PubMed ID: 28401338 [TBL] [Abstract][Full Text] [Related]
12. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer. Knific T; Osredkar J; Smrkolj Š; Tonin I; Vouk K; Blejec A; Frković Grazio S; Rižner TL Gynecol Oncol; 2017 Oct; 147(1):126-132. PubMed ID: 28735628 [TBL] [Abstract][Full Text] [Related]
13. Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer. Wang Y; Han C; Teng F; Bai Z; Tian W; Xue F Int J Gynaecol Obstet; 2017 Jan; 136(1):58-63. PubMed ID: 28099710 [TBL] [Abstract][Full Text] [Related]
14. Potential of an age-stratified CA125 cut-off value to improve the prognostic classification of patients with endometrial cancer. Chao A; Tang YH; Lai CH; Chang CJ; Chang SC; Wu TI; Hsueh S; Wang CJ; Chou HH; Chang TC Gynecol Oncol; 2013 Jun; 129(3):500-4. PubMed ID: 23458702 [TBL] [Abstract][Full Text] [Related]
15. Serum tetranectin and CA125 in endometrial adenocarcinoma. Lundstrøm MS; Høgdall CK; Nielsen AL; Nyholm HC Anticancer Res; 2000; 20(5C):3903-6. PubMed ID: 11268474 [TBL] [Abstract][Full Text] [Related]
16. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Moore RG; Brown AK; Miller MC; Badgwell D; Lu Z; Allard WJ; Granai CO; Bast RC; Lu K Gynecol Oncol; 2008 Aug; 110(2):196-201. PubMed ID: 18495222 [TBL] [Abstract][Full Text] [Related]
17. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. Jiang T; Huang L; Zhang S BMC Cancer; 2015 May; 15():396. PubMed ID: 25964114 [TBL] [Abstract][Full Text] [Related]
18. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698 [TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer. Bian J; Sun X; Li B; Ming L Technol Cancer Res Treat; 2017 Aug; 16(4):435-439. PubMed ID: 27562869 [TBL] [Abstract][Full Text] [Related]
20. HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status. O'Toole SA; Huang Y; Norris L; Power Foley M; Shireen R; McDonald S; Kamran W; Ibrahim N; Ward M; Thompson C; Murphy C; D'Arcy T; Farah N; Heron E; O'Leary JJ; Abu Saadeh F; Gleeson N Gynecol Oncol; 2021 Feb; 160(2):514-519. PubMed ID: 33213897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]